Matthew J Loza

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
    Matthew J Loza
    Immunology Biomarkers, Janssen Research and Development, LLC, Malvern, PA, USA
    Respir Res 13:12. 2012
  2. ncbi Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis
    Matthew J Loza
    Department of Biomarkers, Centocor Research and Development, Inc, 145 King of Prussia Road, Radnor, PA 19087, USA
    Clin Vaccine Immunol 18:931-9. 2011
  3. ncbi Asthma and gender impact accumulation of T cell subtypes
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Respir Res 11:103. 2010
  4. ncbi beta-Agonist enhances type 2 T-cell survival and accumulation
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:235-44. 2007
  5. ncbi Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 121:750.e1-5.e3. 2008
  6. ncbi Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA
    Blood 107:2052-60. 2006
  7. ncbi Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle
    Anna M Misior
    Wake Forest University Health Sciences, Department of Internal Medicine and Center for Human Genomics, Medical Center Blvd, Winston Salem, NC 27157, USA
    Am J Respir Cell Mol Biol 41:24-39. 2009
  8. ncbi Assembly of inflammation-related genes for pathway-focused genetic analysis
    Matthew J Loza
    Center for Human Genomics, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina, United States of America
    PLoS ONE 2:e1035. 2007
  9. ncbi T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus
    Matthew J Loza
    Center for Human Genomics, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Cell Immunol 271:110-7. 2011
  10. ncbi Purification of peripheral blood natural killer cells
    Bice Perussia
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Univeristy, Philadelphia, PA, USA
    Methods Mol Med 107:147-61. 2005

Detail Information

Publications13

  1. ncbi Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
    Matthew J Loza
    Immunology Biomarkers, Janssen Research and Development, LLC, Malvern, PA, USA
    Respir Res 13:12. 2012
    ..This study sought to evaluate the systemic inflammatory profile associated with COPD and to assess the impact of tumor necrosis factor neutralization on systemic inflammation...
  2. ncbi Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis
    Matthew J Loza
    Department of Biomarkers, Centocor Research and Development, Inc, 145 King of Prussia Road, Radnor, PA 19087, USA
    Clin Vaccine Immunol 18:931-9. 2011
    ..This study supports the need for further exploration of anti-TNF therapy for chronic sarcoidosis patients, particularly for those expressing the highest serum levels of TNF-α...
  3. ncbi Asthma and gender impact accumulation of T cell subtypes
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Respir Res 11:103. 2010
    ..We sought to establish whether CD3+CD28-mediated and antigen-independent accumulation of type 1 and type 2 T cells differs significantly between nonasthmatic and asthmatic populations...
  4. ncbi beta-Agonist enhances type 2 T-cell survival and accumulation
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:235-44. 2007
    ..beta-Adrenergic receptor ligands (beta-agonists) subserve numerous physiologic processes but also function as pathogenic or therapeutic agents in numerous diseases with inflammatory components...
  5. ncbi Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 121:750.e1-5.e3. 2008
    ....
  6. ncbi Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA
    Blood 107:2052-60. 2006
    ..These findings identify direct effects of beta2AR activation on T-cell subtypes and suggest a complex role for GPCRs and PKA activity in modulating T-cell functions...
  7. ncbi Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle
    Anna M Misior
    Wake Forest University Health Sciences, Department of Internal Medicine and Center for Human Genomics, Medical Center Blvd, Winston Salem, NC 27157, USA
    Am J Respir Cell Mol Biol 41:24-39. 2009
    ....
  8. ncbi Assembly of inflammation-related genes for pathway-focused genetic analysis
    Matthew J Loza
    Center for Human Genomics, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina, United States of America
    PLoS ONE 2:e1035. 2007
    ..For existing genome-wide association data, this list of key inflammation-related genes and associated subpathways can facilitate comprehensive inflammation pathway- focused association analyses...
  9. ncbi T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus
    Matthew J Loza
    Center for Human Genomics, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Cell Immunol 271:110-7. 2011
    ..These results suggest that functional defects in T(regs), rather than reduced T(reg) numbers, are important for the loss of peripheral tolerance in lupus. Presentation of this defect may serve as a biomarker for untreated disease...
  10. ncbi Purification of peripheral blood natural killer cells
    Bice Perussia
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Univeristy, Philadelphia, PA, USA
    Methods Mol Med 107:147-61. 2005
  11. ncbi Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Allergy Clin Immunol 120:578-85. 2007
    ..However, the results from studies testing for associations of the I50V and Q551R IL4R genetic variants are conflicting...
  12. ncbi Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer
    Yu Cheng
    Center for Cancer Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Prostate 69:327-35. 2009
    ..However, the interplay between somatic deletion and promoter hypermethylation of TNFRSF10C on PCa development has not been investigated...
  13. ncbi NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production
    Matthew J Loza
    Jefferson Medical College, Kimmel Cancer Center, Department of Microbiology and Immunology, Philadelphia, PA, USA
    Eur J Immunol 32:3453-62. 2002
    ..However, the results of their analysis can be taken as a model for immunotherapeutic approaches with T cells for which a nominal or surrogate antigen is defined...